Creo Medical Group (LON:CREO) Issues Earnings Results

Creo Medical Group (LON:CREO) announced its quarterly earnings results on Friday. The company reported GBX (0.04) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 600 million during the quarter. Creo Medical Group had a return on equity of 32.72% and a net margin of 768.18%.

Creo Medical Group Stock Performance

CREO opened at GBX 14.60 on Friday. The company has a market capitalization of £60.22 million, a price-to-earnings ratio of -14.60 and a beta of 1.62. The business’s 50-day moving average price is GBX 12.08 and its two-hundred day moving average price is GBX 12.16. Creo Medical Group has a 1 year low of GBX 9.52 and a 1 year high of GBX 18.50. The company has a debt-to-equity ratio of 6.90, a current ratio of 5.28 and a quick ratio of 2.19.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Creo Medical Group in a research report on Thursday, April 16th.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.